D57.453
Sickle-cell thalassemia beta plus with cerebral vascular involvement
Clinical Classification Guidelines
Inclusion Terms
- HbS-beta plus with cerebral vascular involvement
- Sickle-cell beta plus with cerebral vascular involvement
Code Also
- , if applicable cerebral infarction (I63.-)
Medical Intelligence & Overview
Sickle-cell thalassemia beta plus with cerebral vascular involvement is a specific subtype of sickle cell disease that combines features of sickle-cell anemia and thalassemia, affecting blood cells and leading to complications in the brain's blood vessels. This condition is characterized by abnormal hemoglobin production, resulting in misshapen red blood cells that can block blood flow, particularly impacting cerebral circulation. Awareness of its causes, symptoms, diagnosis, and management options helps in understanding what this condition entails.
Causes & Symptoms
Clinical Causes: Genetic mutations inherited from parents causing hemoglobin abnormalities Presence of both sickle-cell gene (HbS) and beta-thalassemia gene Combination leads to defective hemoglobin protein, resulting in sickle-shaped red blood cells The abnormal blood cells tend to stick together and block small to medium-sized blood vessels, especially in the brain
Key Symptoms: Frequent episodes of headaches or migraines Transient ischemic attacks (temporary lack of blood flow to the brain) Strokes or other cerebrovascular accidents Dizziness or lightheadedness Cognitive difficulties or changes in mental status Weakness or numbness on one side of the body Visual disturbances or sudden loss of vision Seizures
Diagnostic & Treatment
Diagnosis Path: Hemoglobin electrophoresis to identify abnormal hemoglobin types Complete blood count (CBC) to evaluate red blood cell count and hemoglobin levels Genetic testing to confirm mutations associated with sickle-cell disease and thalassemia Magnetic resonance imaging (MRI) or computed tomography (CT) scans to detect strokes or brain artery abnormalities Transcranial Doppler ultrasound to assess blood flow in cerebral arteries
Treatment Protocols: Hydroxyurea or other medications to reduce the frequency of sickling episodes Blood transfusions to decrease the proportion of sickled cells and prevent strokes Iron chelation therapy to manage iron overload from frequent transfusions Medications to prevent blood clots or manage stroke risk Regular neurological assessments and imaging to monitor brain health Supportive care including pain management, physical therapy, and cognitive support Lifestyle modifications such as staying well-hydrated and avoiding triggers for sickling episodes
Clinical Advice & FAQs
Billing Guidance
Is D57.453 a billable ICD-10 code?
Yes, D57.453 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.453?
Clinical documentation must specify the nature of Sickle-cell thalassemia beta plus with cerebral vascular involvement and any associated comorbidities for accurate reporting.
Cite this Clinical Reference